Evaluation of Thyroid Hormone Replacement Dosing in Overweight and Obese Patients After a Thyroidectomy

COMMENTED

Thyroid

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial

Lancet Diabetes Endocrinol.

Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A

doi: 10.1016/S2213-

Mechanism evaluation of a lifestyle intervention for patients with musculoskeletal pain who are overweight or obese: protocol for a causal mediation analysis

BMJ Open.

Lee H, Wiggers J, Kamper SJ, Williams A, O'Brien KM, Hodder RK, Wolfenden L, Yoong SL, Campbell E, Haskins R, Robson EK, McAuley JH, Williams CM

doi: 10.1136/

Obesity and Bariatric SurgeryThyroid

Thyroid Hormone Status in Overweight Children with Attention Deficit/Hyperactivity Disorder

Horm Res Paediatr.

Langrock C, Hebebrand J, Radowksi K, Hamelmann E, Lücke T, Holtmann M, Legenbauer T, Schmidt B, Frank M, Jöckel KH, Reinehr T

doi: 10.1159/000485620.

RECOMMENDED

Obesity and Bariatric SurgeryThyroid

Altered thyroid function and structure in overweight and obese children and adolescents: reversal after weight loss

J Clin Endocrinol Metab.

Licenziati MR, Valerio G, Vetrani I, De Maria G, Liotta F, Radetti G

doi: 10.1210/jc.2018-02399.

RECOMMENDED

Obesity and Bariatric Surgery

The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Diabetes Care.

Noronha JC, Nishi SK, Braunstein CR, Khan TA, Blanco Mejia S, Kendall CWC, Kahleová H, Rahelić D, Salas-Salvadó J, Leiter LA, Sievenpiper JL

doi: 10.2337/dc18-2270.

Thyroid

Autoimmune thyroid disease and thyroid function test fluctuations in patients with resistance to thyroid hormone

Eur J Endocrinol

Okazaki-Hada M, Nishihara E, Hisakado M, Kudo T, Ito M, Fukata S, Nishikawa M, Akamizu T, Miyauchi A

doi: 10.1530/EJE-21-0584

COMMENTED

Glycemic ControlLipids

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

N Engl J Med.

Bohula E, Wiviott S, McGuire D, Inzucchi S, Kuder J,Im K, Fanola C, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M

doi: 10.1056/NEJMoa1808721..

Obesity and Bariatric Surgery

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial

Circulation.

Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee and Investigators

doi: 10.1161/CIRCULATIONAHA.118.038341.

COMMENTED

Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial

PLoS One.

Bilz S, Flückiger M, Meienberg F, Falconnier C, Keller U, Puder JJ

doi: 10.1371/

Related content

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial

Mechanism evaluation of a lifestyle intervention for patients with musculoskeletal pain who are overweight or obese: protocol for a causal mediation analysis

Thyroid Hormone Status in Overweight Children with Attention Deficit/Hyperactivity Disorder

Altered thyroid function and structure in overweight and obese children and adolescents: reversal after weight loss

The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Autoimmune thyroid disease and thyroid function test fluctuations in patients with resistance to thyroid hormone

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial

Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial